Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis
Copyright © 2020 Elsevier Inc. All rights reserved..
Allergic rhinitis (AR), most presentations of nasal polyposis (NP), and many presentations of chronic rhinosinusitis are type 2high disorders characterized by expression of interleukin (IL)-4, IL-5, and IL-13. Neutralization of IgE with anti-IgE (omalizumab) has proven efficacy in AR. Similarly, in addition to anti-IgE, blockade of IL-5/IL-5 (mepolizumab, reslizumab, benralizumab) and dual blockade of IL-4 and IL-13 with anti-IL-4R (dupilumab) have demonstrated efficacy in NP. However, these agents are expensive and future studies are essential to evaluate cost effectiveness in comparison with current medical and surgical therapies. This article reviews biologics as potential interventions in AR, chronic rhinosinusitis, and NP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Immunology and allergy clinics of North America - 40(2020), 4 vom: 05. Nov., Seite 539-547 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eschenbacher, William [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2021 Date Revised 02.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.iac.2020.06.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315826126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315826126 | ||
| 003 | DE-627 | ||
| 005 | 20231225155744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.iac.2020.06.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315826126 | ||
| 035 | |a (NLM)33012318 | ||
| 035 | |a (PII)S0889-8561(20)30036-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eschenbacher, William |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2021 | ||
| 500 | |a Date Revised 02.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Allergic rhinitis (AR), most presentations of nasal polyposis (NP), and many presentations of chronic rhinosinusitis are type 2high disorders characterized by expression of interleukin (IL)-4, IL-5, and IL-13. Neutralization of IgE with anti-IgE (omalizumab) has proven efficacy in AR. Similarly, in addition to anti-IgE, blockade of IL-5/IL-5 (mepolizumab, reslizumab, benralizumab) and dual blockade of IL-4 and IL-13 with anti-IL-4R (dupilumab) have demonstrated efficacy in NP. However, these agents are expensive and future studies are essential to evaluate cost effectiveness in comparison with current medical and surgical therapies. This article reviews biologics as potential interventions in AR, chronic rhinosinusitis, and NP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allergic rhinitis | |
| 650 | 4 | |a Chronic rhinosinusitis | |
| 650 | 4 | |a Eosinophils | |
| 650 | 4 | |a IgE | |
| 650 | 4 | |a Interleukins | |
| 650 | 4 | |a Nasal polyposis | |
| 650 | 4 | |a Type 2 inflammation | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a IL4 protein, human |2 NLM | |
| 650 | 7 | |a IL4R protein, human |2 NLM | |
| 650 | 7 | |a IL5 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-13 |2 NLM | |
| 650 | 7 | |a Interleukin-4 Receptor alpha Subunit |2 NLM | |
| 650 | 7 | |a Interleukin-5 |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 700 | 1 | |a Straesser, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Knoeddler, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Rung-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Borish, Larry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology and allergy clinics of North America |d 1990 |g 40(2020), 4 vom: 05. Nov., Seite 539-547 |w (DE-627)NLM087751623 |x 1557-8607 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:4 |g day:05 |g month:11 |g pages:539-547 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.iac.2020.06.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 4 |b 05 |c 11 |h 539-547 | ||